Pfizer Lines Up Trio Of US Biosimilar Launches
Bevacizumab, Rituximab And Trastuzumab Slated For US Entry
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
You may also be interested in...
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.